Skip to content
OpenCapital
Get started

OraSure Technologies OSUR COVID-19 — Net revenues

Other product segments

HIV
$13.02M+0.9%
Sample Management Solutions
$9.06M-0.6%
HCV
$2.66M-38.5%
Other Product And Services Revenues
$1.62M+109%
Non-product and services revenues
$1.55M+65.8%
Risk Assessment Testing
$0-100%

Similar metrics at other companies

Moderna logo
MRNACOVID — Total Revenue
$345M+311%
Castle Biosciences logo
CSTLNon-Dermatologic — NET REVENUES
$42.57M+70.1%
GeneDx Holdings logo
WGSDiagnostic Test — Total Revenue
$101.3M+18.1%
Castle Biosciences logo
CSTLDermatologic — NET REVENUES
$41.11M-34.7%
Bio-Rad Laboratories logo
BIOClinical Diagnostics — Net Sales
$363.6M+1.9%
Veracyte logo
VCYTTesting revenue — Total Revenue
$135.09M+25.9%

Other financials

Income statement

See full
Revenue$27.9M-6.7%
Gross profit$11.8M-4.0%
Operating income-$23.3M-31.1%
Net income-$22.4M-39.5%
EPS (diluted)-$0.32-52.4%

Balance sheet

See full
Cash & equivalents$177.0M-28.5%
Total debt$12.7M-10.9%
Total equity$313.3M-20.9%
Total assets$379.2M-17.1%

Cash flow

See full
Operating cash flow-$13.9M+29.6%
CapEx$913.0K+117%
Free cash flow-$14.8M+26.5%

Valuation

See full
Market cap$303.62M+35.3%
Enterprise value$139.32M-1,654%
P/S2.7×+1.3×

Profitability

See full
Gross margin42.2%+0.4pp
Operating margin-68.6%-149pp
Net margin-66.4%-115pp
FCF margin-42.4%-43.3pp

Returns & leverage

See full
Return on equity-21.2%-50.4pp
Debt / equity0×0.0×
Current ratio5.5×-6.9×

Where this comes from

Reported directly by OraSure Technologies in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: OraSure Technologies’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about OraSure Technologies's covid-19 — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OraSure Technologies's COVID-19 — net revenues?
OraSure Technologies (OSUR) reported COVID-19 — net revenues of $18K in Q1 2026.
How has OraSure Technologies's COVID-19 — net revenues changed year-over-year?
OraSure Technologies's COVID-19 — net revenues decreased by 96.1% year-over-year, from $461K to $18K.
What is the long-term trend for OraSure Technologies's COVID-19 — net revenues?
Over 3 years (2021 to 2025), OraSure Technologies's COVID-19 — net revenues has grown at a -43.6% compound annual growth rate (CAGR), from $76.7M to $13.76M.
What does COVID-19 — net revenues mean?
This metric represents the total gross revenue generated from the sale of diagnostic tests, collection devices, and related solutions specifically associated with COVID-19 testing. It serves as a key indicator of the company's exposure to pandemic-related market demand and the subsequent transition of its product portfolio as public health needs evolve. Tracking this revenue stream helps investors assess the impact of fluctuating viral testing volumes on the company's overall top-line performance.